Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.

ABSTRACT: The development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow-based technologies to assess MRD, including approaches using next-generation flow and next-generation sequencing, have provided real-time clinical tools for the sensitive detection and monitoring of MRD in patients with multiple myeloma. Complementary liquid biopsy-based assays are now quickly progressing with some, such as mass spectrometry methods, being very close to clinical use, while others utilizing nucleic acid-based technologies are still developing and will prove important to further our understanding of the biology of MRD. On the regulatory front, multiple retrospective individua

SUBMITTER: Anderson KC 

PROVIDER: S-EPMC9662886 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature